TR200100859T2 - Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi - Google Patents

Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi

Info

Publication number
TR200100859T2
TR200100859T2 TR2001/00859T TR200100859T TR200100859T2 TR 200100859 T2 TR200100859 T2 TR 200100859T2 TR 2001/00859 T TR2001/00859 T TR 2001/00859T TR 200100859 T TR200100859 T TR 200100859T TR 200100859 T2 TR200100859 T2 TR 200100859T2
Authority
TR
Turkey
Prior art keywords
capecitabine
gemcitabine
acetildinal
cancer chemotherapy
cisplatin combination
Prior art date
Application number
TR2001/00859T
Other languages
English (en)
Inventor
Richard Grove William
Daniel Klohs Wayne
Lynn Merriman Ronald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200100859T2 publication Critical patent/TR200100859T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Acetyldinaline'in, gemsitabin, farmasötik olarak kabul edilebilir bir tuzu, kapesitabin veya cisplatin ile kombinasyon halinde, kanser tedavisinde sinerjistik bir etkisi vardir.
TR2001/00859T 1998-09-25 1999-07-08 Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi TR200100859T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
TR200100859T2 true TR200100859T2 (tr) 2001-08-21

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00859T TR200100859T2 (tr) 1998-09-25 1999-07-08 Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi

Country Status (34)

Country Link
US (3) US6469058B1 (tr)
EP (1) EP1115391B1 (tr)
JP (1) JP2002525320A (tr)
KR (1) KR20010075348A (tr)
CN (1) CN1319009A (tr)
AP (1) AP2001002109A0 (tr)
AT (1) ATE225655T1 (tr)
AU (1) AU762079B2 (tr)
BG (1) BG105470A (tr)
BR (1) BR9913952A (tr)
CA (1) CA2342981A1 (tr)
CZ (1) CZ2001905A3 (tr)
DE (1) DE69903458T2 (tr)
DK (1) DK1115391T3 (tr)
EA (1) EA200100369A1 (tr)
EE (1) EE200100187A (tr)
ES (1) ES2185378T3 (tr)
GE (1) GEP20043199B (tr)
HK (1) HK1040190A1 (tr)
HR (1) HRP20010225B1 (tr)
HU (1) HUP0103640A3 (tr)
ID (1) ID30046A (tr)
IL (1) IL141951A0 (tr)
IS (1) IS5888A (tr)
NO (1) NO20011493L (tr)
NZ (1) NZ510504A (tr)
OA (1) OA11659A (tr)
PL (1) PL348673A1 (tr)
PT (1) PT1115391E (tr)
SK (1) SK3602001A3 (tr)
TR (1) TR200100859T2 (tr)
WO (1) WO2000018393A1 (tr)
YU (1) YU22401A (tr)
ZA (1) ZA200102233B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225655T1 (de) * 1998-09-25 2002-10-15 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
RU2240117C1 (ru) * 2003-04-01 2004-11-20 Алтайский государственный медицинский университет Способ лечения больных с местнораспространенными формами плоскоклеточного рака с локализацией в области слизистой оболочки полости рта и ротового отдела глотки
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
CN101268467B (zh) * 2005-07-22 2012-07-18 断层放疗公司 用于评估治疗计划的实施中的质量保证标准的方法和系统
AU2006272742A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
JP2009514559A (ja) 2005-07-22 2009-04-09 トモセラピー・インコーポレーテッド 線量体積ヒストグラムを用いて輪郭構造を生成するシステムおよび方法
US7639853B2 (en) 2005-07-22 2009-12-29 Tomotherapy Incorporated Method of and system for predicting dose delivery
CA2616301A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating delivered dose
JP5060476B2 (ja) 2005-07-22 2012-10-31 トモセラピー・インコーポレーテッド 放射線療法を受けている患者の呼吸位相を検出するシステムおよび方法
US7567694B2 (en) 2005-07-22 2009-07-28 Tomotherapy Incorporated Method of placing constraints on a deformation map and system for implementing same
EP1907065B1 (en) 2005-07-22 2012-11-07 TomoTherapy, Inc. Method and system for adapting a radiation therapy treatment plan based on a biological model
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
EP1906827A4 (en) 2005-07-22 2009-10-21 Tomotherapy Inc SYSTEM AND METHOD FOR EVALUATING A DOSE ADMINISTERED BY A RADIATION THERAPY SYSTEM
CA2616306A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
EP3175886B1 (en) 2005-07-23 2018-06-27 TomoTherapy, Inc. Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
BRPI0722292A2 (pt) 2006-08-31 2014-04-15 Spectrum Pharmaceuticals Inc Sensibilização de células de tumor à terapia com radiação pela administração de agonistas de endotelina
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
AU2010234637B2 (en) 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2962309B1 (en) 2013-02-26 2022-02-16 Accuray, Inc. Electromagnetically actuated multi-leaf collimator
US10189797B2 (en) * 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
WO2020028392A1 (en) 2018-07-30 2020-02-06 Duke University Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ATE225655T1 (de) * 1998-09-25 2002-10-15 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin

Also Published As

Publication number Publication date
DE69903458D1 (de) 2002-11-14
BG105470A (en) 2001-12-29
JP2002525320A (ja) 2002-08-13
SK3602001A3 (en) 2002-07-02
PL348673A1 (en) 2002-06-03
AU5092199A (en) 2000-04-17
EP1115391A1 (en) 2001-07-18
ATE225655T1 (de) 2002-10-15
ID30046A (id) 2001-11-01
OA11659A (en) 2004-12-08
ZA200102233B (en) 2002-06-18
ES2185378T3 (es) 2003-04-16
CA2342981A1 (en) 2000-04-06
PT1115391E (pt) 2003-02-28
NZ510504A (en) 2003-09-26
US20030086965A1 (en) 2003-05-08
HUP0103640A2 (en) 2002-06-29
DE69903458T2 (de) 2003-07-10
GEP20043199B (en) 2004-03-25
HRP20010225B1 (en) 2004-10-31
AU762079B2 (en) 2003-06-19
US6469058B1 (en) 2002-10-22
HK1040190A1 (zh) 2002-05-31
US20030170300A1 (en) 2003-09-11
HRP20010225A2 (en) 2002-04-30
DK1115391T3 (da) 2003-02-10
KR20010075348A (ko) 2001-08-09
NO20011493D0 (no) 2001-03-23
BR9913952A (pt) 2001-06-12
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
CZ2001905A3 (cs) 2001-08-15
WO2000018393A1 (en) 2000-04-06
IS5888A (is) 2001-03-14
AP2001002109A0 (en) 2001-03-31
EP1115391B1 (en) 2002-10-09
EE200100187A (et) 2002-08-15
EA200100369A1 (ru) 2001-10-22
YU22401A (sh) 2004-03-12
NO20011493L (no) 2001-05-23
CN1319009A (zh) 2001-10-24

Similar Documents

Publication Publication Date Title
TR200100859T2 (tr) Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi
BR0207378A (pt) Tratamento de câncer
DE60022367D1 (de) Bandscheibenprothese mit zähnen auf den seiten
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
TR200002299T2 (tr) Epotilon kompozisyonları.
FR11C0037I1 (tr)
DE59200763D1 (de) Zange mit wahlweiser frontaler und seitlicher Einführung.
MY133016A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
TR199800644T2 (tr) Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi.
PL343374A1 (en) Anti-inflammatory, antibacterial benzyl phenol agents
BR0012568A (pt) Inibidores do transporte de fosfato
DE68921080D1 (de) Synergistische, oberflächenaktive Zusammensetzungen.
PT837684E (pt) Composicoes farmaceuticas a base de um sal de diclofenac e de tiocolchicosido
UY26431A1 (es) Quimioterapia de combinación
FI934565A0 (fi) Pyrimidinderivat foer att oeka antitumoeraktiviteten
DK0980205T3 (da) Anvendelse af en kombination af TALL-104 celler med adriamycin eller cisplatin i behandlingen af maligniteter
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
EA200000025A1 (ru) 13-дигидро-3'-азиридиноантрациклины
ES1043499U (es) Tapa-soporte perfeccionada.
KR970020513U (ko) 앞,뒤 구분없는 슬리프
RU97102875A (ru) Способ лечения хронического гастрита с пониженной секрецией
ES1038165U (es) Funda spu "torre" de apertura frontal mediante cremalleras.
ECSP003755A (es) Quimioterapia de combinacion
MX9703460A (es) Composicion de cisplatino en combinacion con 2,2'ditio-bis (etanosulfonato) (dimesna).